168 related articles for article (PubMed ID: 24987171)
21. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
Schadel M; Wu D; Otton SV; Kalow W; Sellers EM
J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
[TBL] [Abstract][Full Text] [Related]
22. Effects of Maribavir on P-Glycoprotein and CYP2D6 in Healthy Volunteers.
Song IH; Ilic K; Murphy J; Lasseter K; Martin P
J Clin Pharmacol; 2020 Jan; 60(1):96-106. PubMed ID: 31385617
[TBL] [Abstract][Full Text] [Related]
23. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.
Streetman DS; Ellis RE; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 1999 Nov; 66(5):535-41. PubMed ID: 10579482
[TBL] [Abstract][Full Text] [Related]
24. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
[TBL] [Abstract][Full Text] [Related]
25. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
26. CYP2D6-related oxidation polymorphism in a Canadian Inuit population.
Jurima-Romet M; Foster BC; Casley WL; Rode A; Vloshinsky P; Huang HS; Geertsen S
Can J Physiol Pharmacol; 1997 Mar; 75(3):165-72. PubMed ID: 9164697
[TBL] [Abstract][Full Text] [Related]
27. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
[TBL] [Abstract][Full Text] [Related]
28. Frequency distribution of dextromethorphan O-demethylation in a Greek population.
Kimiskidis VK; Niopas I; Firinidis PD; Kanaze FI; Gabrieli C; Kazis D; Papagiannopoulos S; Kazis A
Int J Clin Pharmacol Ther; 2005 Mar; 43(3):150-3. PubMed ID: 15792399
[TBL] [Abstract][Full Text] [Related]
29. Dextromethorphan O-demethylation polymorphism in an African-American population.
He N; Daniel HI; Hajiloo L; Shockley D
Eur J Clin Pharmacol; 1999 Aug; 55(6):457-9. PubMed ID: 10492059
[TBL] [Abstract][Full Text] [Related]
30. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
31. Effects of the Chinese herbal formula "Zuojin Pill" on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype.
Qiu F; Liu S; Miao P; Zeng J; Zhu L; Zhao T; Ye Y; Jiang J
Eur J Clin Pharmacol; 2016 Jun; 72(6):689-95. PubMed ID: 27023460
[TBL] [Abstract][Full Text] [Related]
32. An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.
Tamminga WJ; Wemer J; Oosterhuis B; Brakenhoff JP; Gerrits MG; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2001 May; 57(2):143-6. PubMed ID: 11417446
[TBL] [Abstract][Full Text] [Related]
33. Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.
Dickinson GL; Rezaee S; Proctor NJ; Lennard MS; Tucker GT; Rostami-Hodjegan A
J Clin Pharmacol; 2007 Feb; 47(2):175-86. PubMed ID: 17244768
[TBL] [Abstract][Full Text] [Related]
34. Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers.
Wilner KD; Demattos SB; Anziano RJ; Apseloff G; Gerber N
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):43S-47S. PubMed ID: 10771453
[TBL] [Abstract][Full Text] [Related]
35. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans.
Casner PR
J Clin Pharmacol; 2005 Nov; 45(11):1230-5. PubMed ID: 16239355
[TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphism of CYP2D6 in Karnataka and Andhra Pradesh population in India.
Abraham BK; Adithan C; Kiran PU; Asad M; Koumaravelou K
Acta Pharmacol Sin; 2000 Jun; 21(6):494-8. PubMed ID: 11360682
[TBL] [Abstract][Full Text] [Related]
37. CYP2D6 genotype and phenotype relationship in South Indians.
Naveen AT; Prasanna T; Farzana BL; Rajan S; Adithan C
J Postgrad Med; 2006; 52(4):253-6. PubMed ID: 17102541
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota.
Straka RJ; Hansen SR; Walker PF
Clin Pharmacol Ther; 1995 Jul; 58(1):29-34. PubMed ID: 7628180
[TBL] [Abstract][Full Text] [Related]
39. CYP2D6 polymorphism in a Mexican American population.
Mendoza R; Wan YJ; Poland RE; Smith M; Zheng Y; Berman N; Lin KM
Clin Pharmacol Ther; 2001 Dec; 70(6):552-60. PubMed ID: 11753272
[TBL] [Abstract][Full Text] [Related]
40. Alternative methods for CYP2D6 phenotyping: comparison of dextromethorphan metabolic ratios from AUC, single point plasma, and urine.
Chen R; Wang H; Shi J; Hu P
Int J Clin Pharmacol Ther; 2016 May; 54(5):330-6. PubMed ID: 26902503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]